## <sup>1</sup>**Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk**

2 Eileen O. Dareng<sup>1</sup>\*, Jonathan P. Tyrer<sup>2\*</sup>, Daniel R. Barnes<sup>1</sup>, Michelle R. Jones<sup>3</sup>, Xin Yang<sup>1</sup>,  $Katja K.H. Aben<sup>4, 5</sup>, Muriel A. Adank<sup>6</sup>, Simona Agata<sup>7</sup>, Irene L. Andrulis<sup>8, 9</sup>, Hoda Anton-<sup>10</sup>$ Gulver<sup>10</sup>, Natalia N. Antonenkova<sup>11</sup>, Gerasimos Aravantinos<sup>12</sup>, Banu K. Arun<sup>13</sup>, Annelie<br>5 Augustinsson<sup>14</sup>, Judith Balmaña<sup>15, 16</sup>, Elisa V. Bandera<sup>17</sup>, Rosa B. Barkardottir<sup>18, 19</sup>, Daniel Augustinsson<sup>14</sup>, Judith Balmaña<sup>15, 16</sup>, Elisa V. Bandera<sup>17</sup>, Rosa B. Barkardottir<sup>18, 19</sup>, Daniel 6 Barrowdale<sup>1</sup>, Matthias W. Beckmann<sup>20</sup>, Alicia Beeghly-Fadiel<sup>21</sup>, Javier Benitez<sup>22, 23</sup>, Marina Bermisheva<sup>24</sup>, Marcus Q. Bernardini<sup>25</sup>, Line Bjorge<sup>26, 27</sup>, Amanda Black<sup>28</sup>, Natalia V.<br>Bogdanova<sup>11, 29, 30</sup>, Bernardo Bonanni<sup>31</sup>, Ake Borg<sup>32</sup>, James D. Brenton<sup>33</sup>, Agnieszka Bogdanova<sup>11, 29, 30</sup>, Bernardo Bonanni<sup>31</sup>, Ake Borg<sup>32</sup>, James D. Brenton<sup>33</sup>, Agnieszka<br>9 Budzilowska<sup>34</sup>, Ralf Butzow<sup>35</sup>, Saundra S. Buvs<sup>36</sup>, Hui Cai<sup>21</sup>, Maria A. Caligo<sup>37</sup>, Ian Campbell<sup>38,</sup> Budzilowska<sup>34</sup>, Ralf Butzow<sup>35</sup>, Saundra S. Buys<sup>36</sup>, Hui Cai<sup>21</sup>, Maria A. Caligo<sup>37</sup>, Ian Campbell<sup>38,</sup> 10<br>10 <sup>39</sup>, Rikki Cannioto<sup>40</sup>, Hayley Cassingham<sup>41</sup>, Jenny Chang-Claude<sup>42, 43</sup>, Stephen J. Chanock<sup>44</sup>, <sup>39</sup>, Rikki Cannioto<sup>40</sup>, Hayley Cassingham<sup>41</sup>, Jenny Chang-Claude<sup>42, 43</sup>, Stephen J. Chanock<sup>44</sup>,<br>11 Kexin Chen<sup>45</sup>, Yoke-Eng Chiew<sup>46, 47</sup>, Wendy K. Chung<sup>48</sup>, Kathleen B.M. Claes<sup>49</sup>, Sarah 11 Kexin Chen<sup>45</sup>, Yoke-Eng Chiew<sup>46, 47</sup>, Wendy K. Chung<sup>48</sup>, Kathleen B.M. Claes<sup>49</sup>, Sarah<br>12 Colanna<sup>36</sup>, GEMO Study Collaborators<sup>50-52</sup>, GC-HBOC study Collaborators<sup>53</sup>, EMBRACE 12 Colanna<sup>36</sup>, GEMO Study Collaborators<sup>50-52</sup>, GC-HBOC study Collaborators<sup>53</sup>, EMBRACE<br>13 Collaborators<sup>1</sup>, Linda S. Cook<sup>54, 55</sup>, Fergus J. Couch<sup>56</sup>, Mary B. Dalv<sup>57</sup>, Fanny Dao<sup>58</sup>, Eleanor 13 Collaborators<sup>1</sup>, Linda S. Cook<sup>54, 55</sup>, Fergus J. Couch<sup>56</sup>, Mary B. Daly<sup>57</sup>, Fanny Dao<sup>58</sup>, Eleanor 14 Davies<sup>59</sup>, Miguel de la Hoya<sup>60</sup>, Robin de Putter<sup>49</sup>, Joe Dennis<sup>1</sup>, Allison DePersia<sup>61, 62</sup>, Peter Devilee<sup>63, 64</sup>, Orland Diez<sup>65, 66</sup>, Yuan Chun Ding<sup>67</sup>, Jennifer A. Doherty<sup>68</sup>, Susan M. Domchek<sup>69</sup>,<br>16. Thilo Dörk<sup>30</sup>, Andreas du Bois<sup>70, 71</sup>, Matthias Dürst<sup>72</sup>, Diana M. Eccles<sup>73</sup>, Heather A. Eliassen<sup>74,</sup> 16 Thilo Dörk<sup>30</sup>, Andreas du Bois<sup>70, 71</sup>, Matthias Dürst<sup>72</sup>, Diana M. Eccles<sup>73</sup>, Heather A. Eliassen<sup>74,</sup> 17<sup>75</sup>, Christoph Engel<sup>76, 77</sup>, D. Gareth Evans<sup>78, 79</sup>, Peter A. Fasching<sup>20, 80</sup>, James M. Flanagan<sup>81</sup>, <sup>75</sup>, Christoph Engel<sup>76, 77</sup>, D. Gareth Evans<sup>78, 79</sup>, Peter A. Fasching<sup>20, 80</sup>, James M. Flanagan<sup>81</sup>,<br>18 Lenka Foretova<sup>82</sup>, Renée T. Fortner<sup>42</sup>, Eitan Friedman<sup>83, 84</sup>, Patricia A. Ganz<sup>85</sup>, Judy Garber<sup>86</sup>, 18 Lenka Foretova<sup>82</sup>, Renée T. Fortner<sup>42</sup>, Eitan Friedman<sup>83, 84</sup>, Patricia A. Ganz<sup>85</sup>, Judy Garber<sup>86</sup>,<br>19 Francesca Gensini<sup>87</sup>, Graham G. Giles<sup>88-90</sup>, Gord Glendon<sup>8</sup>, Andrew K. Godwin<sup>91</sup>, Marc T. 19 Francesca Gensini<sup>87</sup>, Graham G. Giles<sup>88-90</sup>, Gord Glendon<sup>8</sup>, Andrew K. Godwin<sup>91</sup>, Marc T. Goodman<sup>92</sup>, Mark H. Greene<sup>93</sup>, Jacek Gronwald<sup>94</sup>, OPAL Study Group<sup>95</sup>, AOCS Group<sup>38, 46</sup>,<br>21 Eric Hahnen<sup>53, 96</sup>, Christopher A. Haiman<sup>97</sup>, Niclas Håkansson<sup>98</sup>, Ute Hamann<sup>99</sup>, Thomas V.O. 21 Eric Hahnen<sup>53, 96</sup>, Christopher A. Haiman<sup>97</sup>, Niclas Håkansson<sup>98</sup>, Ute Hamann<sup>99</sup>, Thomas V.O.<br>22 Hansen<sup>100</sup>, Holly R. Harris<sup>101, 102</sup>, Mikael Hartman<sup>103, 104</sup>, Florian Heitz<sup>70, 71, 105</sup>, Michelle A.T. 22 Hansen<sup>100</sup>, Holly R. Harris<sup>101, 102</sup>, Mikael Hartman<sup>103, 104</sup>, Florian Heitz<sup>70, 71, 105</sup>, Michelle A.T.<br>23 Hildebrandt<sup>106</sup>, Estrid Høgdall<sup>107, 108</sup>, Claus K. Høgdall<sup>109</sup>, John L. Hopper<sup>89</sup>, Ruea-Yea 23 Hildebrandt<sup>106</sup>, Estrid Høgdall<sup>107, 108</sup>, Claus K. Høgdall<sup>109</sup>, John L. Hopper<sup>89</sup>, Ruea-Yea<br>24 Huang<sup>110</sup>, Chad Huff<sup>106</sup>, Peter J. Hulick<sup>61, 62</sup>, David G. Huntsman<sup>111-114</sup>, Evgeny N. Imvanitov<sup>115</sup>, 24 Huang<sup>110</sup>, Chad Huff<sup>106</sup>, Peter J. Hulick<sup>61, 62</sup>, David G. Huntsman<sup>111-114</sup>, Evgeny N. Imyanitov<sup>115</sup>,<br>25 KConFab Investigators<sup>38</sup>, HEBON Investigators<sup>116</sup>, Claudine Isaacs<sup>117</sup>, Anna Jakubowska<sup>94, 118</sup>, CONFab Investigators<sup>38</sup>, HEBON Investigators<sup>116</sup>, Claudine Isaacs<sup>117</sup>, Anna Jakubowska<sup>94, 118</sup>,<br>26 Paul A. James<sup>39, 119</sup>, Ramunas Janavicius<sup>120, 121</sup>, Allan Jensen<sup>107</sup>, Oskar Th. Johannsson<sup>122</sup>, Esther Paul A. James<sup>39, 119</sup>, Ramunas Janavicius<sup>120, 121</sup>, Allan Jensen<sup>107</sup>, Oskar Th. Johannsson<sup>122</sup>, Esther<br>27 M. John<sup>123, 124</sup>, Michael E. Jones<sup>125</sup>, Daehee Kang<sup>126-128</sup>, Beth Y. Karlan<sup>129</sup>, Anthony 27 M. John <sup>123, 124</sup>, Michael E. Jones<sup>125</sup>, Daehee Kang<sup>126-128</sup>, Beth Y. Karlan<sup>129</sup>, Anthony<br>28 Karnezis<sup>130</sup>, Linda E. Kelemen<sup>131</sup>, Elza Khusnutdinova<sup>24, 132</sup>, Lambertus A. Kiemenev<sup>4</sup>, Byoung-28 Karnezis<sup>130</sup>, Linda E. Kelemen<sup>131</sup>, Elza Khusnutdinova<sup>24, 132</sup>, Lambertus A. Kiemeney<sup>4</sup>, Byoung-<br>29 Gie Kim<sup>133</sup>, Susanne K. Kiaer<sup>107, 109</sup>, Ian Komenaka<sup>134</sup>, Jolanta Kuprvianczyk<sup>34</sup>, Allison W. Gie Kim<sup>133</sup>, Susanne K. Kjaer<sup>107, 109</sup>, Ian Komenaka<sup>134</sup>, Jolanta Kupryjanczyk<sup>34</sup>, Allison W.<br>30. Kurian<sup>123, 124</sup>, Ava Kwong<sup>135-137</sup>, Diether Lambrechts<sup>138, 139</sup>, Melissa. C. Larson<sup>140</sup>, Conxi SO Kurian<sup>123, 124</sup>, Ava Kwong<sup>135-137</sup>, Diether Lambrechts<sup>138, 139</sup>, Melissa C. Larson<sup>140</sup>, Conxi<br>
31 Lazaro<sup>141</sup>, Nhu D. Le<sup>142</sup>, Goska Leslie<sup>1</sup>, Jenny Lester<sup>129</sup>, Fabienne Lesueur<sup>51, 52, 143</sup>, Douglas A. 31 Lazaro<sup>141</sup>, Nhu D. Le<sup>142</sup>, Goska Leslie<sup>1</sup>, Jenny Lester<sup>129</sup>, Fabienne Lesueur<sup>51, 52, <sup>143</sup>, Douglas A.</sup> 132 Levine<sup>58, 144</sup>, Lian Li<sup>45</sup>, Jingmei Li<sup>145</sup>, Jennifer T. Loud<sup>93</sup>, Karen H. Lu<sup>146</sup>, Jan Lubiński<sup>94</sup>, Eva<br>
33 Machackova<sup>82</sup>, Phuong L. Mai<sup>147</sup>, Siranoush Manoukian<sup>148</sup>, Jeffrey R. Marks<sup>149</sup>, Rayna Kim Machackova<sup>82</sup>, Phuong L. Mai<sup>147</sup>, Siranoush Manoukian<sup>148</sup>, Jeffrey R. Marks<sup>149</sup>, Rayna Kim<br>34 Matsuno<sup>150</sup>, Keitaro Matsuo<sup>151, 152</sup>, Taymaa May<sup>25</sup>, Lesley McGuffog<sup>1</sup>, John R. McLaughlin<sup>153</sup>, 34 Matsuno<sup>150</sup>, Keitaro Matsuo<sup>151, 152</sup>, Taymaa May<sup>25</sup>, Lesley McGuffog<sup>1</sup>, John R. McLaughlin<sup>153</sup>,

 $\mathbf{1}$ 

155 Iain A. McNeish<sup>154, 155</sup>, Noura Mebirouk<sup>51, 52, 143</sup>, Usha Menon<sup>156</sup>, Austin Miller<sup>157</sup>, Roger L.<br>
156 Milne<sup>88-90</sup>, Albina Minlikeeva<sup>158</sup>, Francesmary Modugno<sup>159, 160</sup>, Marco Montagna<sup>7</sup>, Kirsten B. 36 Milne<sup>88-90</sup>, Albina Minlikeeva<sup>158</sup>, Francesmary Modugno<sup>159, 160</sup>, Marco Montagna<sup>7</sup>, Kirsten B.<br>37 Movsich<sup>158</sup>, Elizabeth Munro<sup>161, 162</sup>, , Katherine L. Nathanson<sup>69</sup>, Susan L. Neuhausen<sup>67</sup>, Heli Moysich<sup>158</sup>, Elizabeth Munro<sup>161, 162</sup>, , Katherine L. Nathanson<sup>69</sup>, Susan L. Neuhausen<sup>67</sup>, Heli<br>38 Nevanlinna<sup>163</sup>, Joanne Ngeow Yuen Yie<sup>164, 165</sup>, Henriette Roed Nielsen<sup>166</sup>, Finn C. Nielsen<sup>100</sup>, Nevanlinna<sup>163</sup>, Joanne Ngeow Yuen Yie<sup>164, 165</sup>, Henriette Roed Nielsen<sup>166</sup>, Finn C. Nielsen<sup>100</sup>,<br>39 Liene Nikitina-Zake<sup>167</sup>, Kunle Odunsi<sup>168</sup>, Kenneth Offit<sup>169, 170</sup>, Edith Olah<sup>171</sup>, Siel Olbrecht<sup>172</sup>, Liene Nikitina-Zake<sup>167</sup>, Kunle Odunsi<sup>168</sup>, Kenneth Offit<sup>169, 170</sup>, Edith Olah<sup>171</sup>, Siel Olbrecht<sup>172</sup>,<br>40 Olufunmilayo I. Olopade<sup>173</sup>, Sara H. Olson<sup>174</sup>, Håkan Olsson<sup>14</sup>, Ana Osorio<sup>23, 175</sup>, Laura Papi<sup>87</sup>, Olufunmilayo I. Olopade<sup>173</sup>, Sara H. Olson<sup>174</sup>, Håkan Olsson<sup>14</sup>, Ana Osorio<sup>23, 175</sup>, Laura Papi<sup>87</sup>, Ana Sue K. Park<sup>126-128</sup>, Michael T. Parsons<sup>176</sup>, Harsha Pathak<sup>91</sup>, Inge Sokilde Pedersen<sup>177-179</sup>, Ana Sue K. Park<sup>126-128</sup>, Michael T. Parsons<sup>176</sup>, Harsha Pathak<sup>91</sup>, Inge Sokilde Pedersen<sup>177-179</sup>, Ana<br>42 Peixoto<sup>180</sup>, Tania Peiovic<sup>161, 162</sup>, Pedro Perez-Segura<sup>60</sup>, Jennifer B. Permuth<sup>181</sup>, Beth Peshkin<sup>117</sup>, Peixoto<sup>180</sup>, Tanja Pejovic<sup>161, 162</sup>, Pedro Perez-Segura<sup>60</sup>, Jennifer B. Permuth<sup>181</sup>, Beth Peshkin<sup>117</sup>,<br>43 Paolo Peterlongo<sup>182</sup>, Anna Piskorz<sup>33</sup>, Darya Prokofyeva<sup>183</sup>, Paolo Radice<sup>184</sup>, Johanna Rantala<sup>185</sup>, Paolo Peterlongo<sup>182</sup>, Anna Piskorz<sup>33</sup>, Darya Prokofyeva<sup>183</sup>, Paolo Radice<sup>184</sup>, Johanna Rantala<sup>185</sup>,<br>44 Marjorie J. Riggan<sup>186</sup>, Harvey A. Risch<sup>187</sup>, Cristina Rodriguez-Antona<sup>22, 23</sup>, Eric Ross<sup>188</sup>, Mary Marjorie J. Riggan<sup>186</sup>, Harvey A. Risch<sup>187</sup>, Cristina Rodriguez-Antona<sup>22, 23</sup>, Eric Ross<sup>188</sup>, Mary<br>45 Anne Rossing<sup>101, 102</sup>, Ingo Runnebaum<sup>72</sup>, Dale P. Sandler<sup>189</sup>, Marta Santamariña<sup>175, 190, 191</sup>, Penny Anne Rossing<sup>101, 102</sup>, Ingo Runnebaum<sup>72</sup>, Dale P. Sandler<sup>189</sup>, Marta Santamariña<sup>175, 190, 191</sup>, Penny<br>46 Soucy<sup>192</sup>, Rita K. Schmutzler<sup>53, 96, 193</sup>, V. Wendy Setiawan<sup>97</sup>, Kang Shan<sup>194</sup>, Weiva Sieh<sup>195, 196</sup>, Soucy<sup>192</sup>, Rita K. Schmutzler<sup>53, 96, 193</sup>, V. Wendy Setiawan<sup>97</sup>, Kang Shan<sup>194</sup>, Weiva Sieh<sup>195, 196</sup>,<br>47 Jacques Simard<sup>197</sup>, Christian F. Singer<sup>198</sup>, Anna P. Sokolenko<sup>115</sup>, Honglin Song<sup>199</sup>, Melissa C. 17 Jacques Simard<sup>197</sup>, Christian F. Singer<sup>198</sup>, Anna P Sokolenko<sup>115</sup>, Honglin Song<sup>199</sup>, Melissa C.<br>
18 Southey<sup>88, 90, 200</sup>, Helen Steed<sup>201</sup>, Dominique Stoppa-Lyonnet<sup>50, 202, 203</sup>, Rebecca Sutphen<sup>204</sup>, Southey<sup>88, 90, 200</sup>, Helen Steed<sup>201</sup>, Dominique Stoppa-Lyonnet<sup>50, 202, 203</sup>, Rebecca Sutphen<sup>204</sup>,<br>49 Anthony J. Swerdlow<sup>125, 205</sup>, Yen Yen Tan<sup>206</sup>, Manuel R. Teixeira<sup>180, 207</sup>, Soo Hwang Teo<sup>208, 209</sup>, Anthony J. Swerdlow<sup>125, 205</sup>, Yen Yen Tan<sup>206</sup>, Manuel R. Teixeira<sup>180, 207</sup>, Soo Hwang Teo<sup>208, 209</sup>,<br>50 Kathryn L. Terry<sup>74, 210</sup>, Mary Beth Terry<sup>211</sup>, Mads Thomassen<sup>166</sup>, Pamela J. Thompson<sup>92</sup>, Liv 50 Kathryn L. Terry<sup>74, 210</sup>, Mary Beth Terry<sup>211</sup>, Mads Thomassen<sup>166</sup>, Pamela J. Thompson<sup>92</sup>, Liv<br>51 Cecilie Vestrheim Thomsen<sup>26, 27</sup>, Darcy L. Thull<sup>212</sup>, Marc Tischkowitz<sup>213, 214</sup>, Linda Titus<sup>215</sup>, 51 Cecilie Vestrheim Thomsen<sup>26, 27</sup>, Darcy L. Thull<sup>212</sup>, Marc Tischkowitz<sup>213, 214</sup>, Linda Titus<sup>215</sup>,<br>52 Amanda E. Toland<sup>216</sup>, Diana Torres<sup>99, 217</sup>, Britton Trabert<sup>28</sup>, Ruth Travis<sup>218</sup>, Nadine Tung<sup>219</sup>, 52 Amanda E. Toland<sup>216</sup>, Diana Torres<sup>99, 217</sup>, Britton Trabert<sup>28</sup>, Ruth Travis<sup>218</sup>, Nadine Tung<sup>219</sup>, Shelley S. Tworoger<sup>181, 220</sup>. Ellen Valen<sup>26, 27</sup>, Anne M. van Altena<sup>4</sup>. Annemieke H. van der 53 Shelley S. Tworoger<sup>181, 220</sup>, Ellen Valen<sup>26, 27</sup>, Anne M. van Altena<sup>4</sup>, Annemieke H. van der Hout<sup>221</sup>, Els Van Nieuwenhuysen<sup>172</sup>, Elizabeth J. van Rensburg<sup>222</sup>, Ana Vega<sup>223-225</sup>, Digna Velez 54 Hout<sup>221</sup>, Els Van Nieuwenhuysen<sup>172</sup>, Elizabeth J. van Rensburg<sup>222</sup>, Ana Vega<sup>223-225</sup>, Digna Velez<br>55 Edwards<sup>226</sup>, Robert A. Vierkant<sup>140</sup>, Frances Wang<sup>227, 228</sup>, Barbara Wappenschmidt<sup>53, 96</sup>, Edwards<sup>226</sup>, Robert A. Vierkant<sup>140</sup>, Frances Wang<sup>227, 228</sup>, Barbara Wappenschmidt<sup>53, 96</sup>,<br>56 Penelope M. Webb<sup>95</sup>, Clarice R. Weinberg<sup>229</sup>, Jeffrey N. Weitzel<sup>230</sup>, Nicolas Wentzensen<sup>28</sup>, 956 Penelope M. Webb<sup>95</sup>, Clarice R. Weinberg<sup>229</sup>, Jeffrey N. Weitzel<sup>230</sup>, Nicolas Wentzensen<sup>28</sup>, Emily White<sup>102, 231</sup>, Alice S. Whittemore<sup>123, 232</sup>, Stacey J. Winham<sup>140</sup>, Alicja Wolk<sup>98, 233</sup>, Yin-Ling 57 Emily White<sup>102, 231</sup>, Alice S. Whittemore<sup>123, 232</sup>, Stacey J. Winham<sup>140</sup>, Alicja Wolk<sup>98, 233</sup>, Yin-Ling<br>58 Woo<sup>234</sup>, Anna H. Wu<sup>97</sup>, Li Yan<sup>235</sup>, Drakoulis Yannoukakos<sup>236</sup>, Katia M. Zavaglia<sup>37</sup>, Wei 58 Woo<sup>234</sup>, Anna H. Wu<sup>97</sup>, Li Yan<sup>235</sup>, Drakoulis Yannoukakos<sup>236</sup>, Katia M. Zavaglia<sup>37</sup>, Wei<br>59 Zheng<sup>21</sup>, Argyrios Ziogas<sup>10</sup>, Kristin K. Zorn<sup>147</sup>, Douglas Easton<sup>1,2</sup>, Kate Lawrenson<sup>3, 237</sup>, Anna 29 Zheng<sup>21</sup>, Argyrios Ziogas<sup>10</sup>, Kristin K. Zorn<sup>147</sup>, Douglas Easton<sup>1,2</sup>, Kate Lawrenson<sup>3, 237</sup>, Anna<br>60 DeFazio<sup>46, 47</sup>, Thomas A. Sellers<sup>238</sup>, Susan J. Ramus<sup>239, 240</sup>, Celeste L. Pearce<sup>241, 242</sup>, Alvaro N. 60 DeFazio<sup>46, 47</sup>, Thomas A. Sellers <sup>238</sup>, Susan J. Ramus<sup>239, 240</sup>, Celeste L. Pearce<sup>241, 242</sup>, Alvaro N.<br>61 Monteiro<sup>181</sup>, Julie Cunningham<sup>243</sup>, Ellen L. Goode<sup>243</sup>, Joellen M. Schildkraut<sup>244</sup>, Andrew 61 Monteiro<sup>181</sup>, Julie Cunningham<sup>243</sup>, Ellen L. Goode<sup>243</sup>, Joellen M. Schildkraut<sup>244</sup>, Andrew<br>62 Berchuck<sup>186</sup>, Georgia Chenevix-Trench<sup>176</sup>, Simon A. Gavther<sup>3</sup>, Antonis C. Antoniou<sup>1</sup>, Paul D.P. 62 Berchuck<sup>186</sup>, Georgia Chenevix-Trench<sup>176</sup>, Simon A. Gayther<sup>3</sup>, Antonis C. Antoniou<sup>1</sup>, Paul D.P. 63 Pharoah<sup>1, 2</sup>

 $2^2$  University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology,<br>  $68$  Cambridge UK 68 Cambridge, UK.

 $1$  University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public<br>66 Health and Primary Care Cambridge UK 66 Health and Primary Care, Cambridge, UK.

- $\frac{3}{70}$  Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los<br>70 Angeles CA USA 70 Angeles, CA, USA.
- <sup>4</sup> Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The<br>
<sup>72</sup> Netherlands 72 Netherlands.
- <sup>5</sup> Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
- <sup>6</sup> The Netherlands Cancer Institute Antoni van Leeuwenhoek hospital, Family Cancer Clinic,<br>75 Amsterdam The Netherlands 75 Amsterdam, The Netherlands.
- <sup>7</sup> Veneto Institute of Oncology IOV IRCCS, Immunology and Molecular Oncology Unit,<br>77 Padua Italy 77 Padua, Italy.
- <sup>8</sup> Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for<br>79 Cancer Genetics Toronto ON Canada 79 Cancer Genetics, Toronto, ON, Canada.
- <sup>9</sup> University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada.

81 <sup>10</sup> University of California Irvine, Department of Epidemiology, Genetic Epidemiology<br>82 Besearch Institute Irvine CA USA 82 Research Institute, Irvine, CA, USA.

- <sup>11</sup> N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
- 84 <sup>12</sup> 'Agii Anargiri' Cancer Hospital, Athens, Greece.
- $13$  University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology,<br>86 Houston TX USA 86 Houston, TX, USA.
- <sup>14</sup> Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden.
- <sup>15</sup> Vall d'Hebron Institute of Oncology, Hereditary cancer Genetics Group, Barcelona, Spain.
- <sup>16</sup> University Hospital of Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain.
- $17$  Rutgers Cancer Institute of New Jersey, Cancer Prevention and Control Program, New Brunswick NI USA 91 Brunswick, NJ, USA.
- <sup>18</sup> Landspitali University Hospital, Department of Pathology, Reykjavik, Iceland.
- 93 <sup>19</sup> University of Iceland, BMC (Biomedical Centre), Faculty of Medicine, Reykjavik, Iceland.
- 20 <sup>20</sup> University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg,<br>95 Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, 95 Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany. Germany.
- $2^1$  Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 98 Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN,<br>99 USA. USA.
- 100  $^{22}$  Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
- <sup>23</sup> Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme,<br>102 Madrid Spain 102 Madrid, Spain.

- <sup>24</sup> Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry<br>104 and Genetics Ufa Russia 104 and Genetics, Ufa, Russia.
- <sup>25</sup> Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network,<br>106 Toronto Ontario Canada 106 Toronto, Ontario, Canada.
- <sup>26</sup> Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway.
- <sup>27</sup> University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science,<br>109 Bergen, Norway 109 Bergen, Norway.
- <sup>28</sup> National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 111 **IISA** 111 USA.
- <sup>29</sup> Hannover Medical School, Department of Radiation Oncology, Hannover, Germany.
- <sup>30</sup> Hannover Medical School, Gynaecology Research Unit, Hannover, Germany.
- <sup>31</sup> IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics,<br>115 Milan Italy 115 Milan, Italy.
- 116  $32$  Lund University and Skåne University Hospital, Department of Oncology, Lund, Sweden.
- <sup>33</sup> Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
- <sup>34</sup> Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology<br>119 and Laboratory Diagnostics, Warsaw, Poland 119 and Laboratory Diagnostics, Warsaw, Poland.
- <sup>35</sup> University of Helsinki, Department of Pathology, Helsinki University Hospital, Helsinki, 121 Finland 121 Finland.
- <sup>36</sup> Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA.
- $37$  University Hospital, SOD Genetica Molecolare, Pisa, Italy.
- <sup>38</sup> Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
- <sup>39</sup> The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne,<br>126 Victoria Australia 126 Victoria, Australia.
- $127$ <sup>40</sup> Roswell Park Cancer Institute, Cancer Pathology & Prevention, Division of Cancer 128 Prevention and Population Sciences Buffalo NY USA 128 Prevention and Population Sciences, Buffalo, NY, USA.
- $^{41}$  Division of Human Genetics, The Ohio State University, Department of Internal Medicine, Columbus OH USA 130 Columbus, OH, USA.
- <sup>42</sup> German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany 132 Germany.
- <sup>43</sup> University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University<br>134 Cancer Center Hamburg (UCCH) Hamburg Germany 134 Cancer Center Hamburg (UCCH), Hamburg, Germany.
- <sup>44</sup> National Cancer Institute, National Institutes of Health, Department of Health and Human<br>136 Services Division of Cancer Enidemiology and Genetics Bethesda MD USA 136 Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.

- 137 <sup>45</sup> Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, 138 Tianjin China 138 Tianjin, China.
- <sup>46</sup> The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical<br>140 Research, Sydney New South Wales, Australia 140 Research, Sydney, New South Wales, Australia.
- <sup>47</sup> Westmead Hospital, Department of Gynaecological Oncology, Sydney, New South Wales,<br>142 Australia 142 Australia.
- <sup>48</sup> Columbia University, Departments of Pediatrics and Medicine, New York, NY, USA.
- <sup>49</sup> Ghent University, Centre for Medical Genetics, Gent, Belgium.
- <sup>50</sup> INSERM U830, Department of Tumour Biology, Paris, France.
- 146  $<sup>51</sup>$  Institut Curie, Paris, France.</sup>
- 147 <sup>52</sup> Mines ParisTech, Fontainebleau, France.

<sup>53</sup> Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for<br>149 Familial Breast and Ovarian Cancer Cologne, Germany 149 Familial Breast and Ovarian Cancer, Cologne, Germany.

- <sup>54</sup> University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque,<br>151 NM JISA 151 NM, USA.
- <sup>55</sup> Alberta Health Services, Department of Cancer Epidemiology and Prevention Research,<br>153 Calgary AB Canada 153 Calgary, AB, Canada.
- <sup>56</sup> Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
- <sup>57</sup> Fox Chase Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA.
- <sup>58</sup> Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New <br>157 Nork NY USA 157 York, NY, USA.
- 158 <sup>59</sup> Cambridge, Cambridge, UK.
- <sup>60</sup> CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del <br>160 Hospital Clínico San Carlos), Molecular Opcology Laboratory, Madrid, Spain 160 Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain.
- <sup>61</sup> NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA.
- 162 <sup>62</sup> The University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
- <sup>63</sup> Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands.
- <sup>64</sup> Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands.
- <sup>65</sup> Vall dHebron Institute of Oncology (VHIO), Oncogenetics Group, Barcelona, Spain.
- <sup>66</sup> University Hospital Vall dHebron, Clinical and Molecular Genetics Area, Barcelona, Spain.
- <sup>67</sup> Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, 168 <br>168 USA 168 USA.

 $\bar{\mathbf{r}}$ 

- 169 <sup>68</sup> University of Utah, Huntsman Cancer Institute, Department of Population Health Sciences, 170 Salt Lake City UT USA 170 Salt Lake City, UT, USA.
- 171  $^{69}$  University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center, <br>172 Philadelphia PA USA 172 Philadelphia, PA, USA.
- $70^{70}$  Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology,  $174$  Essen Germany 174 Essen, Germany.
- 175<sup>71</sup> Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic<br>176 Oncology Wiesbaden Germany 176 Oncology, Wiesbaden, Germany.
- 177<sup>72</sup> Jena University Hospital Friedrich Schiller University, Department of Gynaecology, Jena,<br>178 Germany 178 Germany.
- 179 <sup>73</sup> University of Southampton, Faculty of Medicine, Southampton, UK.
- 180  $^{74}$  Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, 181  $\overline{1154}$ 181 USA.
- 182 <sup>75</sup> Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network<br>183 Medicine Boston MA USA 183 Medicine, Boston, MA, USA.
- <sup>76</sup> University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, <br>185 Germany 185 Germany.
- 186 <sup>77</sup> University of Leipzig, LIFE Leipzig Research Centre for Civilization Diseases, Leipzig, Germany 187 Germany.
- <sup>78</sup> University of Manchester, Manchester Academic Health Science Centre, Division of 189 189 Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine<br>190 and Health, Manchester, UK. and Health, Manchester, UK.
- <sup>79</sup> 191<sup>79</sup> St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic<br>1921 Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic 192 Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic<br>193 Medicine, Manchester, UK. Medicine, Manchester, UK.
- $80$  University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology Los Angeles  $CA$  USA 195 Medicine Division of Hematology and Oncology, Los Angeles, CA, USA.
- <sup>81</sup> Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre,<br>197 Department of Surgery and Cancer London UK 197 Department of Surgery and Cancer, London, UK.
- <sup>82</sup> Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and Genetics,<br>199 Brno Czech Republic 199 Brno, Czech Republic.
- 200<sup>83</sup> Chaim Sheba Medical Center, The Susanne Levy Gertner Oncogenetics Unit, Ramat Gan, 201<sup>8</sup> 201 Israel.
- 202 <sup>84</sup> Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel.
- 203  $^{85}$  Jonsson Comprehensive Cancer Centre, UCLA, Schools of Medicine and Public Health,<br>204 Division of Cancer Prevention & Control Research Los Angeles CA USA 204 Division of Cancer Prevention & Control Research, Los Angeles, CA, USA.

205 <sup>86</sup> Dana-Farber Cancer Institute, Cancer Risk and Prevention Clinic, Boston, MA, USA. 206 <sup>87</sup> University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario<br>207 Serio' Medical Genetics Unit Florence Italy 207 Serio', Medical Genetics Unit, Florence, Italy. 208 <sup>88</sup> Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, Australia. 209 <sup>89</sup> The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School<br>210 of Population and Global Health Melbourne Victoria Australia 210 of Population and Global Health, Melbourne, Victoria, Australia. 211 <sup>90</sup> Monash University, Precision Medicine, School of Clinical Sciences at Monash Health,<br>212 Clayton Victoria Australia 212 Clayton, Victoria, Australia. 213 <sup>91</sup> University of Kansas Medical Center, Department of Pathology and Laboratory Medicine,<br>214 Kansas City KS USA 214 Kansas City, KS, USA. 215  $^{92}$  Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer 216 Prevention and Genetics Program Los Angeles CA USA 216 Prevention and Genetics Program, Los Angeles, CA, USA. 217 <sup>93</sup> National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and<br>218 Genetics Bethesda MD USA 218 Genetics, Bethesda, MD, USA. <sup>94</sup> Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland. 220<sup>95</sup> QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, 221 Oueensland Australia 221 Queensland, Australia. 222  $^{96}$  Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for 223 Integrated Oncology (CIO) Cologne Germany 223 Integrated Oncology (CIO), Cologne, Germany. 224  $\frac{97}{225}$  University of Southern California, Department of Preventive Medicine, Keck School of 225 225 Medicine, Los Angeles, CA, USA. 226 <sup>98</sup> Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden. <sup>99</sup> German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg,<br>228 Germany 228 Germany. 100 <sup>100</sup> Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics,<br>230 Copenhagen, Denmark. Copenhagen, Denmark. 231 <sup>101</sup> Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public<br>232 Health Sciences Seattle WA USA 232 Health Sciences, Seattle, WA, USA. <sup>102</sup> University of Washington, Department of Epidemiology, Seattle, WA, USA. 234  $^{103}$  National University of Singapore and National University Health System, Saw Swee Hock<br>235 School of Public Health Singapore Singapore 235 School of Public Health, Singapore, Singapore. <sup>104</sup> National University Health System, Department of Surgery, Singapore, Singapore. 237 <sup>105</sup> Humboldt-UniversitŠt zu Berlin, and Berlin Institute of Health, Department for Gynecology<br>238 with the Center for Oncologic Surgery CharitŽ Campus Virchow-Klinikum, CharitŽ Đ 238 with the Center for Oncologic Surgery CharitŽ Campus Virchow-Klinikum, CharitŽ Đ<br>239 UniversitŠtsmedizin Berlin, corporate member of Freie UniversitŠt Berlin, Berlin, Germany. <sup>239</sup>UniversitŠtsmedizin Berlin, corporate member of Freie UniversitŠt Berlin, Berlin, Germany.

- 240 <sup>106</sup> University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston,<br>241 TX USA 241 TX, USA.
- 242<sup>107</sup> Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, 243 Copenhagen, Denmark.
- 244 <sup>108</sup> University of Copenhagen, Molecular Unit, Department of Pathology, Herlev Hospital, <br>245 Copenhagen Denmark 245 Copenhagen, Denmark.
- 246 <sup>109</sup> University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen, 247 Denmark 247 Denmark.
- 248 <sup>110</sup> Roswell Park Cancer Institute, Center For Immunotherapy, Buffalo, NY, USA.
- 249  $\frac{111}{11}$  BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Ovarian Cancer Research (OVCARE) Program Vancouver BC Canada 250 Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver, BC, Canada.
- 251 <sup>112</sup> University of British Columbia, Department of Pathology and Laboratory Medicine, 252 Vancouver, BC, Canada.
- 253 <sup>113</sup> University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, BC, 254 254 Canada.
- 255 <sup>114</sup> BC Cancer Research Centre, Department of Molecular Oncology, Vancouver, BC, Canada.
- 256 <sup>115</sup> N.N. Petrov Institute of Oncology, St. Petersburg, Russia.
- 257 <sup>116</sup> Coordinating center: The Netherlands Cancer Institute, The Hereditary Breast and Ovarian<br>258 Cancer Research Group Netherlands (HEBON) Amsterdam The Netherlands 258 Cancer Research Group Netherlands (HEBON), Amsterdam, The Netherlands.
- 259 <sup>117</sup> Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
- 260 <sup>118</sup> Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic<br>261 Diagnostics Szczecin Poland 261 Diagnostics, Szczecin, Poland.
- 262 <sup>119</sup> Peter MacCallum Cancer Center, Parkville Familial Cancer Centre, Melbourne, Victoria, <br>263 Australia 263 Australia.
- 264 <sup>120</sup> Vilnius University Hospital Santariskiu Clinics, Hematology, oncology and transfusion<br>265 medicine center Dent of Molecular and Regenerative Medicine Vilnius Lithuania <sup>265</sup>medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius, Lithuania.
- 266 <sup>121</sup> State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
- <sup>122</sup> Landspitali University Hospital, Department of Oncology, Reykjavik, Iceland.
- 268 <sup>123</sup> Stanford University School of Medicine, Department of Epidemiology & Population Health,<br>269 Stanford CA USA 269 Stanford, CA, USA.
- 270  $^{124}$  Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology Stanford CA JISA 271 Division of Oncology, Stanford, CA, USA.

 $\mathbf Q$ 

<sup>125</sup> The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK.

- 273 <sup>126</sup> Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, <br>274 Korea 274 Korea.
- 275 <sup>127</sup> Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, <br>276 Korea 276 Korea.
- 277 <sup>128</sup> Seoul National University, Cancer Research Institute, Seoul, Korea.
- 278 <sup>129</sup> University of California at Los Angeles, David Geffen School of Medicine, Department of 279 Obstetrics and Gynecology Los Angeles CA USA 279 Obstetrics and Gynecology, Los Angeles, CA, USA.
- 280 <sup>130</sup> UC Davis Medical Center, Department of Pathology and Laboratory Medicine, Sacramento, 281 CA USA 281 CA, USA.
- 282 <sup>131</sup> Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA.
- 283 <sup>132</sup> Saint Petersburg State University, Saint Petersburg, Russia.

284 <sup>133</sup> Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology,<br>285 Samsung Medical Center Seoul Korea 285 Samsung Medical Center, Seoul, Korea.

- 286 <sup>134</sup> City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA.
- 287 <sup>135</sup> Cancer Genetics Centre, Hong Kong Hereditary Breast Cancer Family Registry, Happy<br>288 Valley Hong Kong 288 Valley, Hong Kong.
- 289 <sup>136</sup> The University of Hong Kong, Department of Surgery, Pok Fu Lam, Hong Kong.
- 290 <sup>137</sup> Hong Kong Sanatorium and Hospital, Department of Surgery, Happy Valley, Hong Kong.
- 291 <sup>138</sup> VIB Center for Cancer Biology, Leuven, Belgium.
- $1392$   $139$  University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics Leuven Belgium 293 Genetics, Leuven, Belgium.
- 294 <sup>140</sup> Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and<br>295 Informatics Rochester MN USA 295 Informatics, Rochester, MN, USA.
- 296 <sup>141</sup> ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Hereditary<br>297 Cancer Program Barcelona Spain 297 Cancer Program, Barcelona, Spain.
- 298 <sup>142</sup> BC Cancer, Cancer Control Research, Vancouver, BC, Canada.
- 299<sup>143</sup> Inserm U900, Genetic Epidemiology of Cancer team, Paris, France.
- 144 NYU Langone Medical Center, Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer<br>301 Center, New York, NY USA 301 Center, New York, NY, USA.
- 302 <sup>145</sup> Genome Institute of Singapore, Human Genetics Division, Singapore, Singapore.

146 University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology<br>304 and Clinical Cancer Genetics Program Houston TX USA 304 and Clinical Cancer Genetics Program, Houston, TX, USA.

- $147$  Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA,  $164$ 306 USA.
- 1<sup>48</sup> Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Unit of Medical Genetics,<br>308 Department of Medical Oncology and Hematology Milan Italy 308 Department of Medical Oncology and Hematology, Milan, Italy.
- <sup>149</sup> Duke University Hospital, Department of Surgery, Durham, NC, USA.
- <sup>150</sup> University of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, HI, USA.
- 151 <sup>151</sup> Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention, 312 Nagoya, Japan.
- 152 Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, 314 Nagoya, Japan.
- <sup>153</sup> Samuel Lunenfeld Research Institute, Public Health Ontario, Toronto, ON, Canada.
- $154$  Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre,<br>  $154$  Department Surgery & Cancer London LIK 317 Department Surgery & Cancer, London, UK.
- <sup>155</sup> University of Glasgow, Institute of Cancer Sciences, Glasgow, UK.
- $156$  University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials &  $\frac{320}{\text{Methodology}}$  London, LIK 320 Methodology, London, UK.
- $157$   $157$  Roswell Park Cancer Institute, NRG Oncology, Statistics and Data Management Center, 322 Buffalo, NY, USA.
- $158$  323<sup>158</sup> Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, 324 USA.
- $159$   $^{159}$  Magee-Womens Research Institute and Hillman Cancer Center, Womens Cancer Research<br>326 Center Pittsburgh PA JISA 326 Center, Pittsburgh, PA, USA.
- <sup>160</sup> University of Pittsburgh School of Medicine, Division of Gynecologic Oncology,<br>328 Department of Obstetrics Gynecology and Reproductive Sciences Pittsburgh PA USA 328 Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA, USA.
- 161 <sup>329</sup>Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, 330 OR, USA.
- 331  $162$  Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
- 163 University of Helsinki, Department of Obstetrics and Gynecology, Helsinki University<br>1833 Hospital Helsinki Finland <sup>333</sup>Hospital, Helsinki, Finland.
- <sup>164</sup> National Cancer Centre, Cancer Genetics Service, Singapore, Singapore.
- 335 <sup>165</sup> Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, 336 Singapore, 336 Singapore.
- <sup>166</sup> Odense University Hospital, Department of Clinical Genetics, Odence C, Denmark.
- 338  $167$  Latvian Biomedical Research and Study Centre, Riga, Latvia.

- <sup>168</sup> Roswell Park Cancer Institute, Department of Gynecologic Oncology, Buffalo, NY, USA.
- <sup>169</sup> Memorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of 341 Cancer Biology and Genetics New York NY USA 341 Cancer Biology and Genetics, New York, NY, USA.
- $170$  Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of  $343$  Medicine New York NY USA 343 Medicine, New York, NY, USA.
- <sup>171</sup> National Institute of Oncology, Department of Molecular Genetics, Budapest, Hungary.
- $172$  University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics<br>346 and Gynaecology and Leuven Cancer Institute, Leuven, Belgium 346 and Gynaecology and Leuven Cancer Institute, Leuven, Belgium.
- <sup>173</sup> The University of Chicago, Center for Clinical Cancer Genetics, Chicago, IL, USA.
- $174$  Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York NY USA 349 New York, NY, USA.
- 350<sup>175</sup> Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
- $176$  QIMR Berghofer Medical Research Institute, Department of Genetics and Computational  $352$  Riology Brisbane Queensland Australia 352 Biology, Brisbane, Queensland, Australia.
- <sup>177</sup> Aalborg University Hospital, Molecular Diagnostics, Aalborg, Denmark.
- <sup>178</sup> Aalborg University Hospital, Clinical Cancer Research Center, Aalborg, Denmark.
- <sup>179</sup> Aalborg University, Department of Clinical Medicine, Aalborg, Denmark.
- <sup>180</sup> Portuguese Oncology Institute, Department of Genetics, Porto, Portugal.
- <sup>181</sup> Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA.
- $182$  IFOM the FIRC Institute of Molecular Oncology, Genome Diagnostics Program, Milan,  $1859$  Italy 359 Italy.
- <sup>183</sup> Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia.
- 184 361 <sup>184</sup> Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic<br>1862 Bisk and Genetic Testing, Department of Besearch Milan, Italy 362 Risk and Genetic Testing, Department of Research, Milan, Italy.
- 363 <sup>185</sup> Karolinska Institutet, Clinical Genetics, Stockholm, Sweden.
- <sup>186</sup> Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA.
- <sup>187</sup> Yale School of Public Health, Chronic Disease Epidemiology, New Haven, CT, USA.
- <sup>188</sup> Fox Chase Cancer Center, Population Studies Facility, Philadelphia, PA, USA.
- 189 367 <sup>189</sup> National Institute of Environmental Health Sciences, NIH, Epidemiology Branch, Research<br>368 Triangle Park NC USA
- 368 Triangle Park, NC, USA.
- 369 <sup>190</sup> Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain.

- 370 <sup>191</sup> Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, <sup>371</sup> Spain 371 Spain.
- 372 <sup>192</sup> Centre Hospitalier Universitaire de Québec Université Laval Research Center, Genomics<br>373 Center, Québec City OC Canada 373 Center, Québec City, OC, Canada.
- 274 <sup>193</sup> Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for 375 Molecular Medicine Cologne (CMMC) Cologne Germany 375 Molecular Medicine Cologne (CMMC), Cologne, Germany.
- 194 Hebei Medical University, Fourth Hospital, Department of Obstetrics and Gynaecology, Shijiazhuang China 377 Shijiazhuang, China.
- $195$   $^{195}$  Icahn School of Medicine at Mount Sinai, Department of Population Health Science and  $379$  Policy New York NY USA 379 Policy, New York, NY, USA.
- $\frac{196}{196}$  Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York NY USA 381 New York, NY, USA.
- 382  $^{197}$  Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Genomic 383 383 Center, Québec City, QC, Canada.
- 198 Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, 285 Austria 385 Austria.
- <sup>199</sup> University of Cambridge, Department of Public Health and Primary Care, Cambridge, UK.
- $200$  The University of Melbourne, Department of Clinical Pathology, Melbourne, Victoria,  $\frac{200}{4}$  Australia 388 Australia.
- 201 Royal Alexandra Hospital, Department of Obstetrics and Gynecology, Division of 390 Gynecologic Opeology Edmonton Alberta Canada 390 Gynecologic Oncology, Edmonton, Alberta, Canada.
- 391  $^{202}$  Institut Curie, Service de Génétique, Paris, France.
- 392  $^{203}$  Université Paris Descartes, Paris, France.
- <sup>204</sup> University of South Florida, Epidemiology Center, College of Medicine, Tampa, FL, USA.
- <sup>205</sup> The Institute of Cancer Research, Division of Breast Cancer Research, London, UK.
- $2^{206}$  Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna,  $2^{206}$  Austria 396 Austria.
- $207 \, \text{University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal.}$
- <sup>208</sup> Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor, <br>399 Malaysia 399 Malaysia.
- 400  $^{209}$  University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, Malaysia 401 Malaysia.
- 402<sup>210</sup> Brigham and Women's Hospital and Harvard Medical School, Obstetrics and Gynecology<br>403 Enidemiology Center Boston MA USA <sup>403</sup>Epidemiology Center, Boston, MA, USA.

- 2<sup>211</sup> Columbia University, Department of Epidemiology, Mailman School of Public Health, New<br>205 North NY USA 405 York, NY, USA.
- 406  $^{212}$  Magee-Womens Hospital, University of Pittsburgh School of Medicine, Department of Medicine, Pittsburgh PA USA 407 Medicine, Pittsburgh, PA, USA.
- 408 <sup>213</sup> McGill University, Program in Cancer Genetics, Departments of Human Genetics and Oncology Montréal OC Canada 409 Oncology, Montréal, QC, Canada.
- 410 <sup>214</sup> University of Cambridge, Department of Medical Genetics, Cambridge, UK.
- 411 <sup>215</sup> Dartmouth College, Geisel School of Medicine, Hanover, NH, USA.
- 412 <sup>216</sup> The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH,  $113$  ISA 413 USA.
- 414  $\frac{217}{\pi}$ Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, Colombia.
- 415 <sup>218</sup> University of Oxford, Cancer Epidemiology Unit, Oxford, UK.
- 416 <sup>219</sup> Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, MA, 417 USA.
- 418  $^{220}$  Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA,  $^{119}$ 419 USA.
- 420<sup>221</sup> University Medical Center Groningen, University Groningen, Department of Genetics, 421 Groningen, The Netherlands.
- 422 <sup>222</sup> University of Pretoria, Department of Genetics, Arcadia, South Africa.
- <sup>223</sup> Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
- 424 <sup>224</sup> Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
- 425 <sup>225</sup> Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo<br>426 Hospitalario Universitario de Santiago SERGAS Santiago de Compostela Spain 426 Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
- 226 Vanderbilt University Medical Center, Division of Quantitative Sciences, Department of Approximate Cynecology, Department of Biomedical Sciences, Women's Health Research 428 Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, A29 Nashville, TN, USA. Nashville, TN, USA.
- 430  $^{227}$  Duke Cancer Institute, Cancer Control and Population Sciences, Durham, NC, USA.
- 431  $^{228}$  Duke University Hospital, Department of Community and Family Medicine, Durham, NC, 432 ISA 432 USA.
- 433  $^{229}$  National Institute of Environmental Health Sciences, NIH, Biostatistics and Computational Riology Branch Research Triangle Park NC USA 434 Biology Branch, Research Triangle Park, NC, USA.
- 435  $^{230}$  City of Hope, Clinical Cancer Genomics, Duarte, CA, USA.
- 436 <sup>231</sup> Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

- $2^{32}$  Stanford University School of Medicine, Department of Biomedical Data Science, Stanford,  $\overline{C}$  A JISA 438 CA, USA.
- 439 <sup>233</sup> Uppsala University, Department of Surgical Sciences, Uppsala, Sweden.
- <sup>234</sup> University of Malaya, Department of Obstetrics and Gynaecology, University of Malaya<br>441 Medical Centre Kuala Lumpur Malaysia 441 Medical Centre, Kuala Lumpur, Malaysia.
- <sup>235</sup> Hebei Medical University, Fourth Hospital, Department of Molecular Biology, Shijiazhuang,<br>443 China <sup>443</sup>China.
- 444 <sup>236</sup> National Centre for Scientific Research 'Demokritos', Molecular Diagnostics Laboratory, <br>445 INRASTES Athens Greece 445 INRASTES, Athens, Greece.
- 446  $^{237}$  Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-<br>447 Sinai Medical Centre, Department of Obstetrics and Gynecology, Los Angeles, CA, USA <sup>447</sup>Sinai Medical Centre, Department of Obstetrics and Gynecology, Los Angeles, CA, USA.
- 448 $^{238}$  1032 Royal Pass Road, Tampa, FL, USA.
- 449  $^{239}$  University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine,  $^{450}$ 450 Sydney, New South Wales, Australia.
- 451  $^{240}$  University of NSW Sydney, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, New South Wales, Australia 452 New South Wales, Australia.
- 241 University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, 254 MILISA 454 MI, USA.
- 455  $\frac{242}{156}$  University of Southern California Norris Comprehensive Cancer Center, Department of 456 Preventive Medicine Keck School of Medicine Los Angeles CA USA 456 Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA.
- 457 <sup>243</sup> Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, <br>458 MN USA 458 MN, USA.
- $2^{244}$  Emory University, Department of Epidemiology, Rollins School of Public Health, Atlanta,  $60 \overline{64}$  USA 460 GA, USA.
- 
- 462 \*These authors had equal contributions.
- 463 Corresponding Author: pp10001@medschl.cam.ac.uk

464

# <sup>465</sup>**Running Title: Polygenic Risk Modelling for Prediction of Epithelial Ovarian**

- <sup>466</sup>**Cancer Risk**
- 

#### <sup>468</sup>**Abstract**

<sup>469</sup>Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to 470 improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) 471 effects in models could improve predictive performance over standard approaches of <sup>472</sup>PRS construction. Here, we implemented computationally-efficient, penalized, logistic 473 regression models (lasso, elastic net, stepwise) to individual level genotype data and a <sup>474</sup>Bayesian framework with continuous shrinkage, "select and shrink for summary 475 statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk 476 prediction. We developed the models in a dataset consisting of 23,564 non-mucinous <sup>477</sup>EOC cases and 40,138 controls participating in the Ovarian Cancer Association 478 Consortium (OCAC) and validated the best models in three populations of different 479 ancestries: prospective data from 198,101 women of European ancestry; 7,669 women 480 of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 *BRCA1* and <sup>481</sup>12,337 *BRCA2* pathogenic variant carriers of European ancestry. In the external 482 validation data, the model with the strongest association for non-mucinous EOC risk 483 derived from the OCAC model development data was the S4 model (27,240 SNPs) with 484 odds ratios (OR) of  $1.38(95\% \text{ CI} : 1.28-1.48, \text{AUC} : 0.588)$  per unit standard deviation, in 485 women of European ancestry; 1.14(95%CI:1.08–1.19,AUC:0.538) in women of East <sup>486</sup>Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; <sup>487</sup>hazard ratios of 1.37(95%CI:1.30–1.44,AUC:0.592) in *BRCA1* pathogenic variant 488 carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in *BRCA2* pathogenic variant carriers. 489 Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have 490 clinical utility in ovarian cancer prevention programs.

491

#### <sup>492</sup>**INTRODUCTION**

<sup>493</sup>Rare mutations in known high and moderate penetrance susceptibility genes (*BRCA1*, <sup>494</sup>*BRCA2*, *BRIP1*, *PALB2*, *RAD51C*, *RAD51D* and the mis-match repair genes) account 495 for about 40 percent of the inherited component of EOC disease risk  $(1,2)$ . Genome 496 wide association studies (GWAS), reviewed in Kar et. al. and Jones et. al. (1,3), have 497 identified 39 common (minor allele frequency  $[MAF] > 0.05$ ) susceptibility variants 498 which together explain about 6% of the heritability of EOC. Polygenic risk scores <sup>499</sup>(PRS) provide an opportunity for refined risk stratification in the general population as 500 well as in carriers of rare moderate or high risk alleles (4,5).

<sup>501</sup>A PRS is calculated as the weighted sum of the number of risk alleles carried for a 502 specified set of genetic variants. The best approach to identify the set of variants and 503 their weights in order to optimize the predictive power of a PRS is unknown. A 504 common approach involves selecting a set of variants that reach a threshold for <sup>505</sup>association based on the p-value for each variant with or without clumping and pruning  $506$  to remove highly correlated variants  $(6,7)$ . More complex prediction models, based on <sup>507</sup>machine learning approaches that do not assume variant independence have also been 508 used to construct PRS for complex traits in humans (8,9). To date, these methods have 509 produced only modest gains in predictive power for highly polygenic phenotypes (8,10). 510 Penalized regression approaches such as the lasso, elastic net and the adaptive lasso 511 have also been used for the joint estimation of variant effects using individual level data 512 for large data sets (11). While they have the potential advantage of improving 513 performance, the major drawback of these methods is the high computational burden 514 required to fit the models  $(11,12)$ .

<sup>515</sup>In this study, we present a novel implementation of computationally-efficient PRS 516 models using two approaches: 1) penalized regression models including the lasso, 517 elastic net and minimax concave penalty, for use when individual genotype data are 518 available; and 2) a Bayesian regression model with continuous shrinkage priors on 519 variant effect sizes, for use in broader settings where summary statistics are available, 520 hereafter referred to as the "select and shrink with summary statistics" (S4) method. We 521 compare these models with two commonly used methods, stepwise regression with p-522 value thresholding and LDPred.

#### <sup>523</sup>**MATERIALS (SUBJECTS) AND METHODS**

#### <sup>524</sup>*EOC Histotypes*

<sup>525</sup>EOC is a highly heterogeneous phenotype with five major histotypes for invasive 526 disease – high-grade serous, low-grade serous, endometrioid, clear cell and mucinous 527 histotype. The mucinous histotype is the least common and its origin is the most 528 controversial with up to 60% of diagnosed cases of mucinous ovarian cancer often 529 being misdiagnosed metastasis from non-ovarian sites (13). Recent molecular analyses 530 have concluded that most primary invasive mucinous cases are not extra-ovarian 531 metastases (14). However, accurate diagnosis relies on expert histopathology and 532 immuno-histochemical profiling (15), which remains a challenge in clinical practice and 533 can be an issue in different cohorts from different time periods. Therefore, in this study, 534 we performed PRS modelling and association testing for all cases of invasive EOC, 535 excluding mucinous cases, hereafter referred to as non-mucinous EOC.

#### <sup>536</sup>*Model Development Study Population*

<sup>537</sup>We used genotype data from 23,564 invasive non-mucinous EOC cases and 40,138 538 controls with >80% European ancestry from 63 case-control studies included in the 539 Ovarian Cancer Association Consortium (OCAC) for model development. The study 540 protocol was approved by the institutional review boards of the Brigham and Women's 541 Hospital and Harvard T.H. Chan School of Public Health, and those of participating 542 registries as required. The distribution of cases by histotype was high-grade serous 543 (13,609), low-grade serous  $(2,749)$ , endometrioid  $(2,877)$ , clear cell  $(1,427)$ , and others <sup>544</sup>(2,902). All mucinous EOC histotypes (2,587) were excluded. Sample collection, 545 genotyping and quality control have been previously described (16). Genotype data 546 were imputed to the Haplotype Reference Consortium reference panel on the Michigan <sup>547</sup>Imputation server, using 470,825 SNPs that passed quality control. Of the 32 million SNPs imputed, 10 million had imputation  $r^2 > 0.3$  and were included in this analysis.

#### <sup>549</sup>*Model Validation Study Population*

# <sup>550</sup>**UK Biobank Population**

551 We validated the best-fitting PRS models developed in the OCAC data in 657 prevalent 552 and incident cases of invasive EOC (346 serous, 98 endometrioid, 51 clear cell and 162 553 other) and 198,101 female controls of European ancestry from the UK Biobank. As with 554 the model development data, all mucinous histotypes (166) were excluded. Samples <sup>555</sup>were genotyped using either the Affymetrix UK BiLEVE Axiom Array or Affymetrix <sup>556</sup>UK Biobank Axiom Array (which share 95% marker content), and then imputed to a 557 combination of the Haplotype Reference Consortium, the 1000Genomes phase 3 and 558 the UK10K reference panels (17). We restricted analysis to genetically confirmed

559 females of European/white British ancestry. We excluded individuals if they were 560 outliers for heterozygosity, had low genotyping call rate <95%, had sex chromosome 561 aneuploidy, or if they were duplicates (cryptic or intended) (16). All SNPs selected in 562 the model development phase were available in the UK Biobank.

#### <sup>563</sup>**Non-European Ancestry Population**

564 We investigated transferability of the best-fitting PRS models to populations of non-<sup>565</sup>European ancestry using genotype data from females of East Asian and African 566 ancestries that had been genotyped as part of the OCAC OncoArray Project (18,19). <sup>567</sup>Women of East Asian ancestry - 2,841 non-mucinous invasive EOC (1,960 high-grade 568 serous, 136 low-grade serous, 400 endometrioid, 271 clear cell, 74 other histotypes) 569 and 4,828 controls - were identified using a criterion of >80% Asian ancestry. This 570 group included samples collected from population-based studies in China, Japan, Korea, <sup>571</sup>Malaysia as well as samples from studies conducted in the US, Europe and Australia. 572 Details of these data have been previously described (18). Similarly, women of African 573 ancestry - 368 cases of non-mucinous invasive EOC (261 high-grade serous, 35 low-574 grade serous, 47 endometrioid, 7 clear cell, 53 other histoptypes) and 704 controls, 575 mainly from studies conducted in the US, were identified using a criterion of  $>80\%$ 576 African ancestry.as described previously (19).

## <sup>577</sup>*BRCA1/BRCA2* **Pathogenic Variant Carrier Population**

<sup>578</sup>We also assessed the performance of the best-fitting PRS models in women of European 579 ancestry (>80% European ancestry) with the pathogenic *BRCA1* and *BRCA2* variants 580 from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). We used <sup>581</sup>genotype data from 18,915 *BRCA1* (2,053 invasive EOC cases – 712 serous, 115

582 endometrioid, 9 clear cell, 1217 unknown/other) and 12,337 *BRCA2* (717 invasive EOC 583 cases – 26 serous, 4 endometrioid, 1 clear cell, 686 unknown/other) pathogenic variant 584 carriers from 63 studies contributing to CIMBA for independent model validation. 585 Details of the study population and sample collection have been described previously <sup>586</sup>(16). Genotyping, data quality control measures, intercontinental ancestry assessment 587 and imputation to the HRC reference panel are as described for the OCAC study 588 population.

# <sup>589</sup>**PRS from Meta-analysis of Summary Statistics**

<sup>590</sup>We leveraged the increase in sample size resulting from a meta-analysis of EOC risk 591 associations, using both the CIMBA and OCAC data described above, to explore 592 performance of PRS approaches based on summary statistics.

#### <sup>593</sup>**Statistical Analysis**

#### <sup>594</sup>*Polygenic Risk Models*

595 For all PRS models, we created scores as linear functions of the allele dosage in the

general form  $PRS_i = \sum_j^p x_{ij} \beta_j$ 596 general form  $PRS_i = \sum_j^p x_{ij} \beta_j$  where genotypes are denoted as x (taking on the minor

597 allele dosages of 0, 1 and 2), with  $x_{ij}$  representing the *i*th individual for the *j*th SNP

598 (out of  $p$  SNPs) on an additive log scale and  $\beta_j$  represents the weight - the log of the

599 odds ratio - of the  $j$ th SNP. We used different approaches to select and derive the

600 optimal weights,  $\beta_j$ , in models as described below.

# <sup>601</sup>*Penalized logistic regression models: the lasso, elastic net and minimax concave*  <sup>602</sup>*penalty*

<sup>603</sup>A penalized logistic regression model for a set of SNPs aims to identify a set of 604 regression coefficients that minimize the regularized loss function given by

$$
plr(x; \lambda, \kappa) = \begin{cases} x - \lambda sign(x) / (1 - \kappa) & \text{if } |x| < \lambda / \kappa \text{ and } |(x)| > \lambda \\ x & \text{if } |x| \geq \frac{\lambda}{\kappa} \\ 0 & \text{if } |(x)| < \lambda \end{cases}
$$

605 where x is the effect estimate of a SNP,  $\lambda$  is the tuning parameter and  $\kappa$  is the threshold 606 (penalty) for different regularization paths.  $\lambda$  and  $\kappa$  are parameters that need to be 607 chosen during model development to optimize performance. The lasso, elastic net, <sup>608</sup>minimax concave penalty (MCP), and p-value thresholds are instances of the function 609 with different  $\kappa$  values. We minimized the winner's curse effect on inflated effect 610 estimates for rare SNPs by penalizing rarer SNPs more heavily than common SNPs. 611 Details are provided in the Supplementary Methods.

<sup>612</sup>We used a two-stage approach to reduce computational burden without a corresponding 613 loss in predictive power. The first stage was a SNP selection stage using a sliding <sup>614</sup>windows approach, with 5.5Mb data blocks and a 500kb overlap between blocks. SNP 615 selection was performed for each block and selected SNPs were collated. Single SNP 616 association analyses were then run, and all SNPs with a  $\chi^2$  test statistic of less than 2.25 <sup>617</sup>were excluded. Penalized regression models were applied to the remaining SNPs 618 using  $\lambda$  values of 3.0 and  $\kappa$  values of 0.0, 0.2, 0.4, 0.6, 0.8 and 1.0. SNPs selected in any 619 of these models were included in subsequent analyses.

620 In the second stage, we fit penalized regression models to the training dataset with  $\lambda$ 621 values ranging from 3.0 to 5.5 in increments of 0.1 iterated over  $\kappa$  values from -3.0 to 1 622 in increments of 0.1. The lasso model ( $\kappa = 0$ ) for each value of  $\lambda$  was fitted first, to 623 obtain a unique maximum. From the fitted maximum the  $\kappa$  value was changed, and the <sup>624</sup>model refitted.

<sup>625</sup>We applied this two-stage approach with five-fold cross-validation (**Figure 1**). The 626 variants and their weights from the two-stage penalized logistic regression modelling in 627 the training data were used to calculate the area under the receiver operating 628 characteristic curve (AUC) in the test data. We repeated this process for each cross-629 validation iteration to obtain a mean AUC for each combination of  $\lambda$  and  $\kappa$ .

<sup>630</sup>Finally, we selected the tuning and threshold parameters from the lasso, elastic net and 631 minimax concave penalty models with the maximum mean cross-validated AUC and 632 fitted penalized logistic regression models with these parameters to the entire OCAC 633 dataset to obtain SNP weights for PRS scores.

#### <sup>634</sup>*Stepwise logistic regression with variable P-value threshold*

635 This model is a general PLR model with  $\kappa=1$ . As with the other PLR models, we 636 investigated various values for  $\lambda$  values (corresponding to a variable P-value threshold 637 for including a SNP in the model). However, we observed that the implementation of 638 this model on individual level data was more difficult than for other  $\kappa$  values because 639 the model would sometimes converge to a local optimum rather than the global 640 optimum. Therefore, we applied an approximate conditional and joint association <sup>641</sup>analysis using summary level statistics correcting for estimated LD between SNPs,

642 using a reference panel of 5,000 individual level genotype OCAC data as described in 643 Yang et.al (20). Details are provided in the Supplementary Methods.

<sup>644</sup>*LDPred* 

<sup>645</sup>LDPred is a Bayesian approach that adjusts GWAS summary statistics for the effects of 646 LD by shrinking the posterior mean effect size of each genetic marker based on a point-647 normal prior on the effect sizes and LD information from an external reference panel. <sup>648</sup>We derived seven candidate polygenic risk scores assuming the fractions of associated 649 variants were 0.001, 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0 respectively (21) using an LD 650 reference panel of 503 samples of European ancestries from the 1000 Genomes phase 3 651 release and effect estimates from the genome wide association analysis on the OCAC 652 model development data.

# <sup>653</sup>*Select and shrink using summary statistics (S4)*

<sup>654</sup>The S4 algorithm is similar to the PRS-CS algorithm (22) which is a Bayesian approach 655 that uses summary statistics and between-SNP correlation data from a reference panel to 656 generate the PRS scores by placing a continuous shrinkage prior on effect sizes. We 657 adapted this method with penalization of rarer SNPs by correcting for the standard 658 deviation resulting in the selection of fewer SNPs. To implement this algorithm, we <sup>659</sup>varied three parameters, *a, b,* <sup>φ</sup>, which together control the degree of shrinkage of effect 660 estimates.  $\Phi$ , the overall shrinkage parameter, is influenced by values of *a* which 661 control shrinkage of effect estimates around 0 and *b* which control shrinkage of larger 662 effect estimates. Smaller values of *a* result in more severe shrinkage of effect estimates 663 than larger values. Conversely, smaller values of *b* produce less severe shrinkage than 664 larger values.

<sup>665</sup>We generated summary statistics for each cross-validation training set and selected the 666 parameters that gave the best results on average from the cross-validation and applied 667 these to the set of summary statistics for the complete OCAC data set to obtain the final 668 set of weights.

#### <sup>669</sup>*PRS based on meta-analysis of OCAC-CIMBA summary statistics*

<sup>670</sup>We conducted a meta-analysis of the EOC associations in *BRCA1* variant carriers, <sup>671</sup>*BRCA2* variant carriers and the participants participating in OCAC using previously 672 described methodological approaches (16). Additional details are provided in the <sup>673</sup>Supplementary Methods. We constructed two PRS models using results from the <sup>674</sup>OCAC-CIMBA meta-analysis: the Select and Shrink (OCAC-CIMBA) PRS and the 675 Stepwise (OCAC-CIMBA) PRS. To construct the Select and Shrink (OCAC-CIMBA) <sup>676</sup>PRS, we applied the *a, b* and <sup>φ</sup> parameters from the Select and Shrink model described <sup>677</sup>above to the summary statistics from the meta-analysis to obtain a different set of SNPs 678 and weights. We generated the Stepwise (OCAC-CIMBA) PRS by using histotype-679 specific results from the meta-analysis. We selected all SNPs that were genome-wide 680 significant at nominal thresholds ( $p \leq 5x10^{-8}$ ), along with any independent signals in the 681 same region with  $p<10^{-5}$  from the histotype specific analyses for low-grade serous, <sup>682</sup>high-grade serous, endometrioid, clear cell ovarian cancer and non-mucinous invasive 683 EOC.

#### <sup>684</sup>*Polygenic risk score performance.*

685 The best lasso, elastic net, stepwise and S4 models from the model development stage <sup>686</sup>were validated using two independent data sources: the UK Biobank data and <sup>687</sup>*BRCA1/BRCA2* pathogenic variant carriers from the CIMBA. In the UK Biobank data,

<sup>688</sup>we evaluated discriminatory performance of the models using the AUC and examined 689 the association between standardized PRS and risk of non-mucinous EOC using 690 logistic regression analysis. For the CIMBA data, we assessed associations for each 691 version of the PRS and invasive non-mucinous EOC risk using weighted Cox regression <sup>692</sup>methods previously described (5). PRSs in the CIMBA data were scaled to the same <sup>693</sup>PRS standard deviations as the OCAC data, meaning that per standard deviation hazard <sup>694</sup>ratios estimated on CIMBA data are comparable to PRS associations in the OCAC and <sup>695</sup>UK Biobank data. The regression models were adjusted for birth cohort (<1920, 1920- 696 1929, 1930-1939, 1940-1949,  $\geq$ 1950) and the first four ancestry informative principal 697 components (calculated separately by iCOGS/OncoArray genotyping array) and <sup>698</sup>stratified by Ashkenazi Jewish ancestry and country. Absolute risks by PRS percentiles <sup>699</sup>adjusting for competing risks of mortality from other causes were calculated as 700 described in the Supplementary Material.

#### <sup>701</sup>*Transferability of PRS scores to non-European Ancestry*

<sup>702</sup>We implemented two straightforward approaches to disentangle the role of ancestry on 703 polygenic risk scoring. We selected homogenous ancestral samples by using a high cut-704 off criterion of 80% ancestry and we standardized the polygenic risk scores by mean-705 centering within each population. These approaches led to a more uniform distribution 706 of polygenic risk scores within each ancestral population. Further adjustments using 707 principal components of ancestry did not attenuate risk estimates.

## <sup>708</sup>**Data Availability**

709 OncoArray germline genotype data for the OCAC studies have been deposited at the <sup>710</sup>European Genome-phenome Archive (EGA; https://ega-archive.org/), which is hosted

711 by the EBI and the CRG, under accession EGAS00001002305. Summary results are 712 available from the Ovarian Cancer Association Consortium <sup>713</sup>(http://ocac.ccge.medschl.cam.ac.uk/). A subset of the OncoArray germline genotype 714 data for the CIMBA studies will be made publically available through the database of <sup>715</sup>Genotypes and Phenotypes (dbGaP) under accession phs001321.v1.p1. The complete 716 data set will not be made publically available because of restraints imposed by the ethics 717 committees of individual studies; requests for further data can be made to the Data 718 Access Coordination Committee (http://cimba.ccge.medschl.cam.ac.uk/)

#### <sup>719</sup>**Ethics Statement**

<sup>720</sup>All study participants provided written informed consent and participated in research or 721 clinical studies at the host institute under ethically approved protocols. The studies and

722 their approving institutes are listed in the Supplementary Material (Ethics Statement)

<sup>723</sup>**Results** 

#### <sup>724</sup>*Model development*

725 For models based on individual level genotype data, the elastic net model had the best 726 predictive accuracy (model parameters:  $\lambda = 3.3$ ,  $\kappa = -2.2$ , AUC=0.586) Predictive accuracy 727 for the lasso model  $(\lambda = 3.3, \text{ AUC} = 0.583)$  was slightly lower (**Table 1**). The optimal 728 value of  $\lambda$  obtained from regularization paths for the MCP model was 3.3. Further 729 reductions in the degree of penalization for the MCP models did not improve prediction 730 accuracy. Therefore, the best MCP model was equivalent to the lasso model. For 731 models based on summary statistics, the best-fitting S4 model had the best performance 732 (a=2.75, b=2,  $\varphi$ =3e-6, AUC=0.593), whereas the best LDPred model had the poorest

733	performance of the methods tested ( $\rho$ =0.001, AUC=0.552). The mean odds ratios per
734	standard deviation are shown in <b>Table 1</b> along with the number of SNPs included in the
735	final model when the models were built with the relevant parameters using the complete
736	dataset. All SNPs selected and the associated weights for each model are provided in
737	Supplementary Tables $1 - 6$ . Given the poorer performance of the LD pred model and
738	the very large number of SNPs included in the final model it was not considered for
739	further validation in other datasets.

Model Number of SNPs\* Tuning parameter for best performance AUC OR per 1 SD of PRS 95% CI a) Models based on individual level genotype data Lasso 1,403  $\lambda = 3.3$  0.583 1.35 1.30 – 1.39 Elastic net 10,797  $\lambda = 3.3$ ,  $\kappa = -2.2$  0.586 1.36 1.31 – 1.40 MCP  $1,403$   $\lambda=3.3$  0.583  $1.35$   $1.30-1.39$ b) Models based on summary statistics LDPred 5,291,719  $\rho = 0.001$  0.552 1.21 1.13 – 1.29 Stepwise 22  $\lambda = 5.4$  0.572 1.30 1.26 – 1.34 Select and Shrink (OCAC) 27,240 a=2.75, b=2, φ=3e-6 0.593 1.39 1.34 – 1.44

<sup>740</sup>**Table 1: Performance of different PRS models in five-fold cross validation of OCAC data** 

Abbreviations: AUC-Area Under the Receiver Operating Characteristic (ROC) Curve AUC); OR-Odds Ratio; SD-Standard deviation; PRS-Polygenic Risk Score; CI-Confidence Interval. NA-Not Applicable.

\* Number of SNPs in PRS model run on full OCAC data set after selection of model parameters

#### <sup>741</sup>*Model validation in women of European ancestry: general population (UK Biobank)*

#### <sup>742</sup>*and BRCA1/BRCA2 pathogenic variant carriers (CIMBA)*

743 The best AUC estimates derived from cross-validation are likely to be upwardly biased <sup>744</sup>due to overfitting. Therefore, we used the UK Biobank data as an external validation 745 dataset. Overall the PLR models performed slightly better in the UK Biobank data than 746 the model development data (**Table 2**). Of the models developed using the OCAC <sup>747</sup>model development data, the association between PRS and non-mucinous EOC was 748 strongest with the Select and Shrink derived PRS (OR per unit SD=1.38, 95%CI:1.28– 749 1.48) and slightly lower for the lasso PRS (OR per unit SD=1.37, 95%CI:1.27–1.48),

750	the elastic net PRS (OR per unit $SD=1.36$ , 95%CI:1.26–1.47) and the stepwise PRS
751	model (OR per unit SD=1.35, 95%CI:1.26–1.46). In BRCA1 and BRCA2 variant
752	carriers, prediction accuracy was generally higher among BRCA2 carriers than BRCA1
753	carriers. Consistent with results from the general population in the UK Biobank, the
754	Select and Shrink PRS model also had the strongest association and predictive accuracy
755	for invasive EOC risk in both <i>BRCA1</i> (HR per unit SD=1.37, 95%CI:1.30-1.44,
756	AUC=0.592) carriers and <i>BRCA2</i> carriers (HR per unit SD=1.51, 95%CI:1.36–1.67,
757	AUC=0.624). The PRS models developed using the OCAC-CIMBA meta-analysis
758	results had better discriminative ability in the UK Biobank than the PRS models
759	developed using only OCAC data. Compared with the Select and Shrink model using
760	only OCAC data, the Select and Shrink PRS model derived from the meta-analysis had
761	fewer SNPs $(n=18,007)$ , a stronger association with invasive EOC risk (OR per unit
762	$SD=1.42$ , 95%CI:1.32–1.54) and better predictive accuracy (AUC=0.596). Similarly,
763	the Stepwise model from the OCAC-CIMBA meta-analysis performed better than the
764	Stepwise model from only OCAC data (OR per unit SD=1.39, 95%CI:1.29–1.50,
765	AUC=0.595), but included more SNPs $(n=36)$

<sup>766</sup>**Table 2: External validation of PRS models in European populations using data from UK**  <sup>767</sup>**Biobank and CIMBA** 





Abbreviations: AUC-Area Under the Receiver Operating Characteristic Curve; OR-Odds Ratio; HR-Hazards ratio

\*results in CIMBA are overfitted as the CIMBA data was used for model development

† HR are adjusted for birth cohort and the first four ancestry informative principal components. AUC were estimated from models fitting only the PRS as the independent variable.

768





# **Table 3: Association between polygenic risk scores and non-mucinous EOC by PRS percentiles and ancestry**



OR: Odds Ratio; CI: Confidence Interval.

#### <sup>389</sup>*Absolute Risk of Developing Ovarian Cancer by PRS percentiles*

<sup>390</sup>We estimated cumulative risk of EOC experienced between birth and the age of 80 within <sup>391</sup>PRS percentiles for women in the general population (**Figure 2**), by applying the odds ratio 392 from the PRS models to age-specific population incidence and mortality data for England in <sup>393</sup>2016. For *BRCA1* and *BRCA2* pathogenic variant carriers, we applied the estimated hazard 394 ratios from PRS models to age-specific incidence rates obtained from Kuchenbaecker et al. <sup>395</sup>(23).

396 For women in the general population, the estimated cumulative risks of EOC by age 80 for 397 women at the 99<sup>th</sup> centile of the PRS distribution were 2.24%, 2.18%, 2.54% and 2.81% for 398 the lasso, elastic net, stepwise and S4 models, respectively. In comparison, the absolute risks 399 of EOC by age 80 for women at the  $1<sup>st</sup>$  centile were 0.76%, 0.78%, 0.64% and 0.56% for the 400 lasso, elastic net, stepwise and S4 models, respectively.

<sup>401</sup>The absolute risks of developing EOC in *BRCA1* and *BRCA2* pathogenic variant carriers 402 were considerably higher than for women in the general population (Figures S1:Cumulative 403 risk of ovarian cancer risk in *BRCA1* carriers by polygenic risk score percentiles and S2: <sup>404</sup>Cummulative risk of ovarian cancer risk in *BRCA2* carriers by polygenic risk score <sup>405</sup>percentiles). The estimated absolute risk of developing ovarian cancer by age 80 for *BRCA1* 406 carriers at the 99<sup>th</sup> PRS centiles were 63.2%, 66.3%, 59.0% and 68.4% for the lasso, elastic 407 net, stepwise and S4 models, respectively. The corresponding absolute risks for women at the 408  $1<sup>st</sup> PRS$  centile were 27.7%, 25.6%, 30.8% and 24.2%. Absolute risks of developing EOC 409 were lower for *BRCA2* carriers than *BRCA1* carriers, with absolute risks for women in the 410 99<sup>th</sup> centile being 36.3%, 36.3%, 33.0% and 36.9%; and absolute risks for women in the 1<sup>st</sup> 411 centile being 7.10%, 7.12%, 8.24% and 6.92% for the lasso, elastic net, stepwise and S4

412 models, respectively. Absolute risks for *BRCA1* and *BRCA2* carriers at the  $10^{th}$  and  $90^{th}$ 413 percentile are provided in Supplementary Table 7.

414

# <sup>415</sup>*PRS distribution and ancestry*

<sup>416</sup>To investigate the transferability of the PLR derived PRS to other populations, we applied the 417 scores to women of African  $(N=1,072)$  and Asian  $(N=7,669)$  ancestry genotyped as part of 418 the OncoArray project. In general, the distributions of the raw polygenic scores were 419 dependent on both the statistical methods used in SNP selection and ancestral group. PRS 420 models that included more variants had less dispersion, such that the elastic net models had 421 the least between individual variation in all ancestral groups (standard deviation= $0.15, 0.19$ ) 422 and 0.22 for individuals of Asian, African and European ancestries respectively), while the 423 distributions from the stepwise models were the most dispersed (standard deviation  $= 0.23$ , <sup>424</sup>0.27 and 0.30 for individuals of Asian, African and European ancestries respectively). As 425 expected, given the variation in variant frequencies by population, the distribution of 426 polygenic scores was significantly different across the three ancestral groups, with the least 427 dispersion among women of Asian ancestry and the most variation in women of European 428 ancestry. The difference in polygenic risk score distribution was minimized after correction 429 for ancestry by standardizing the PRS to have unit standard deviation using the control 430 subjects for each ancestral group. For comparison, we investigated the use of the first 20 <sup>431</sup>principal components to correct for ancestry and we obtained similar results.

432 High PRSs were significantly associated with risk of non-mucinous EOC in both Asian and <sup>433</sup>African ancestries (**Table 4**), although the effects were weaker than in women of European <sup>434</sup>ancestry. For example, with the lasso model, the odds ratio (95% CI) per unit standard 435 deviation increment in polygenic score was estimated to be  $1.16$  (1.11–1.22) in women of







### <sup>452</sup>**Discussion**

453 Genetic risk profiling with polygenic risk scores has led to actionable outcomes for cancers 454 such as breast and prostate (24,25). Previous PRS scores for invasive EOC risk in the general 455 population and *BRCA1/BRCA2* pathogenic variant carriers have been based on genetic 456 variants for which an association with EOC risk had been established at nominal genome-457 wide significance (4,5,26–28). Here, we explored the predictive performance of 458 computationally-efficient, penalized, regression methods in modelling joint SNP effects for <sup>459</sup>EOC risk prediction in diverse populations and compared them with common approaches. By <sup>460</sup>leveraging the correlation between SNPs which do not reach nominal genome-wide 461 thresholds and including them in PRS models, the polygenic risk scores derived from <sup>462</sup>penalized regression models in this analysis provide stronger evidence of association with <sup>463</sup>risk of non-mucinous EOC than previously published PRSs in both the general population 464 and in *BRCA1/BRCA2* pathogenic variant carriers.

465 Recently, Barnes et. al derived a PRS score using 22 SNPs that were significantly associated <sup>466</sup>with high-grade serous EOC risk in GWAS (PRSHGS) to predict EOC risk in *BRCA1/BRCA2* <sup>467</sup>pathogenic variant carriers (5). To make effect estimates obtained in this analysis comparable 468 to the effect estimates obtained from the  $PRS_{HGS}$ , we standardized all PRSs using the <sup>469</sup>standard deviation from unaffected *BRCA1/BRCA2* carriers; all PRS models in this analysis 470 except the Stepwise (OCAC only) had higher effect estimates (5). However, the <sup>471</sup>corresponding AUCs were higher for the PRSHGS model (0.604 for *BRCA1* carriers and 0.667 472 for *BRCA2* carriers), most likely as a result of inclusion of other predictors (birth cohort and 473 principal components) in the model. The AUC estimates for women in the general 474 population, as estimated from the UK Biobank, are slightly higher than estimates from

475 previously published PRS models for overall EOC risk by Wei et al  $(AUC=0.57)$  and Yang et 476 al (AUC=0.58)  $(26,28)$ 

<sup>477</sup>In theory, polygenic risk profiling has the potential for clinical utility, being the earliest 478 measurable contributor to risk which may lead to actionable outcomes. The level of risk among women considered to have a high polygenic risk score, for example women in the  $95<sup>th</sup>$ 480 percentile, for all of the models we considered approaches the same level of risk conferred by 481 pathogenic variants in moderate penetrance genes such as *FANCM* (RR=2.1, 95%CI=1.1– <sup>482</sup>3.9) and *PALB2* (RR=2.91 95%CI=1.40–6.04) (29,30). The inclusion of other risk factors 483 such as family history of ovarian cancer, presence of rare pathogenic variants, age at <sup>484</sup>menarche, oral contraceptive use, hormone replacement therapy, parity, and endometriosis in 485 combination with the PRS models could potentially improve risk stratification as has been 486 implemented in the CanRisk tool (www.canrisk.org), which currently uses a PRS model 487 based on 36 SNPs with the potential to use other PRS models (31,32).

<sup>488</sup>An important consideration in the clinical utility of polygenic risk scores is the degree to 489 which results are applicable to diverse populations. We found that the discriminative ability 490 varied substantially by ancestral group. As expected, given that the model development 491 dataset consisted entirely of women of European ancestry, the models had greater 492 discriminative power in women of European ancestry, relative to women of African and East 493 Asian ancestry. We observed greater attenuation of discriminative ability in East Asian 494 populations than African populations. This finding is in contrast to what one would expect 495 given human demographic history, and results from genome wide association studies for <sup>496</sup>EOC (18,19,33,34). One possible explanation for this disparity is the small sample size and <sup>497</sup>imprecise effect estimates for women of African ancestry in this study, due to the larger 498 differences in allele frequency between this population and that of the cohort used to develop

499 the model. Although the model development data for this analysis was predominantly women 500 of European ancestry, the models developed using our approach performed substantially 501 better in women of African ancestry than a PRS model developed by combining 24 published 502 GWAS SNPS associated with non-mucinous EOC, for which the odds of EOC risk was 1.20 503 fold per standard deviation of PRS (19).

504 Further refinements to our models, by exploring other penalty functions, may improve the 505 predictive value of the PRS. However, this approach may be complicated by difficulties that 506 arise due to the correlation structure between SNPs. Another option to optimizing the models 507 could be varying the penalization function based on prior knowledge. In genomic regions that 508 are known to have variants associated with EOC, one is more likely to find other risk-509 associated variants. Therefore, varying the penalty function in these regions such that more <sup>510</sup>SNPs are selected into the model may improve the PRS. Finally, as more functional data 511 become available, modifying penalty functions to incorporate functional data may further 512 improve the PRS. Current approaches for incorporating functional annotation have resulted in 513 only modest gains in prediction accuracy for complex traits such as breast cancer, celiac 514 disease, type 2 diabetes and rheumatoid arthritis, much of which is attributed to the SNPs 515 selected in the models and not the functional annotation (35).

516 The UK Biobank, our model validation dataset for women in the general population, had a 517 small number of invasive EOC cases with a disproportionately high number of mucinous 518 cases (166 of the 823 invasive EOC cases or  $\sim$  20%). Furthermore, cases of the serous 519 histotype could not be classified as either high-grade or low-grade. Therefore, we could not 520 investigate EOC histotype-specific polygenic scores. As the serous histotype is the most 521 common, it is possible that a high-grade serous EOC specific polygenic score may have 522 better predictive value than a non-mucinous polygenic score.

#### <sup>523</sup>*Conclusion*

524 In conclusion, our results indicate that using the lasso model for individual level genotype 525 data and the S4 model for summary level data in polygenic risk score construction provide an 526 improvement in risk prediction for non-mucinous EOC over more common approaches. Our 527 approach overcomes the computational limitations in the use of penalized methods for large 528 scale genetic data, particularly in the presence of highly-correlated SNPs and the use of cross-529 validation for parameter estimation is preferred. In practical terms, the polygenic risk score 530 provides sufficient discrimination, particularly for women of European ancestry, to be 531 considered for inclusion in risk prediction and prevention approaches for EOC in the future. <sup>532</sup>Further studies are required to optimize these polygenic risk scores in ancestrally diverse 533 populations and to validate their performance with the inclusion of other genetic and lifestyle 534 risk factors.

<sup>535</sup>**Acknowledgements and Funding** 

536 Full acknowledgement and funding details are provided in the Supplementary Material

537<br>538

# <sup>538</sup>**Conflicts of Interest**

<sup>539</sup>Anna DeFazio has received a research grant from AstraZeneca, not directly related to the 540 content of this manuscript. Matthias W. Beckmann conducts research funded by Amgen, 541 Novartis and Pfizer. Peter A. Fashing conducts research funded by Amgen, Novartis and 542 Pfizer. He received Honoraria from Roche, Novartis and Pfizer. Allison W. Kurian reports 543 research funding to her institution from Myriad Genetics for an unrelated project. Usha <sup>544</sup>Menon owns stocks in Abcodia Ltd. Rachel A. Murphy is a consultant for Pharmavite. The 545 other authors declare no conflicts of interest.

#### <sup>546</sup>**References**

547 1. Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 548 ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol.<br>549 2017:147(3):705–13. <sup>549</sup>2017;147(3):705–13.

- 550 2. Lyra PCM, Rangel LB, Monteiro ANA. Functional Landscape of Common Variants<br>551 Associated with Susceptibility to Epithelial Ovarian Cancer. Curr Epidemiol Rep. 2020 551 Associated with Susceptibility to Epithelial Ovarian Cancer. Curr Epidemiol Rep. 2020<br>552 Mar 1:7(1):49–57. Mar 1;7(1):49–57.
- 553 3. Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, et al. Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future 554 Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future<br>555 Directions. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored 555 Directions. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored<br>556 Am Soc Prev Oncol. 2018:27(4):395–404. Am Soc Prev Oncol. 2018;27(4):395-404.
- 557 4. Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al.<br>558 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in 558 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in<br>559 BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 01;109(7). <sup>559</sup>BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 01;109(7).
- 560 5. Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, et al. Polygenic<br>561 six scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and 561 risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and 562 BRCA2 pathogenic variants. Genet Med Off J Am Coll Med Genet. 2020 Jul 15; <sup>562</sup>BRCA2 pathogenic variants. Genet Med Off J Am Coll Med Genet. 2020 Jul 15;
- 563 6. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007 Oct:17(10):1520–8. from genome-wide association studies. Genome Res. 2007 Oct;17(10):1520–8.
- 565 7. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM,<br>566 0'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia 566 <sup>O'</sup>Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia<br>567 and bipolar disorder. Nature. 2009 Aug 6:460(7256):748–52. and bipolar disorder. Nature. 2009 Aug 6;460(7256):748–52.
- <sup>568</sup>8. Abraham G, Kowalczyk A, Zobel J, Inouye M. Performance and robustness of 569 penalized and unpenalized methods for genetic prediction of complex human disease.<br>570 Genet Epidemiol. 2013 Feb:37(2):184–95. <sup>570</sup>Genet Epidemiol. 2013 Feb;37(2):184–95.
- 571 9. Habier D, Fernando RL, Kizilkaya K, Garrick DJ. Extension of the bayesian alphabet for genomic selection. BMC Bioinformatics. 2011 May 23:12:186. for genomic selection. BMC Bioinformatics. 2011 May 23;12:186.
- 573 10. Szymczak S, Biernacka JM, Cordell HJ, González-Recio O, König IR, Zhang H, et al.<br>574 Machine learning in genome-wide association studies. Genet Epidemiol. 2009:33 Suppl 574 Machine learning in genome-wide association studies. Genet Epidemiol. 2009;33 Suppl<br>575 1:S51-57. <sup>575</sup>1:S51-57.
- 576 11. Privé F, Aschard H, Blum MGB. Efficient Implementation of Penalized Regression for<br>577 Genetic Risk Prediction. Genetics. 2019;212(1):65–74. <sup>577</sup>Genetic Risk Prediction. Genetics. 2019;212(1):65–74.
- 578 12. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized regression on summary statistics. Genet Epidemiol. 2017:41(6):469–80. <sup>579</sup>regression on summary statistics. Genet Epidemiol. 2017;41(6):469–80.
- <sup>580</sup>13. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol. 2016 Apr 1;27:i53–7.
- 581 14. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The<br>582 molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019 582 molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019<br>583 02;10(1):3935.  $02;10(1):3935.$

584 15. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al.<br>585 A combination of the immunohistochemical markers CK7 and SATB2 is highly 585 A combination of the immunohistochemical markers CK7 and SATB2 is highly<br>586 sensitive and specific for distinguishing primary ovarian mucinous tumors from 586 sensitive and specific for distinguishing primary ovarian mucinous tumors from<br>587 colorectal and appendiceal metastases. Mod Pathol Off J U S Can Acad Pathol Inc. 587 colorectal and appendiceal metastases. Mod Pathol Off J U S Can Acad Pathol Inc.<br>588 2019:32(12):1834–46. <sup>588</sup>2019;32(12):1834–46.

- 589 16. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al.<br>590 Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian 590 Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May:49(5):680–91. <sup>591</sup>cancer. Nat Genet. 2017 May;49(5):680–91.
- 592 17. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank<br>593 resource with deep phenotyping and genomic data. Nature. 2018:562(7726):203–9. resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.
- 594 18. Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, et al. Genome-wide<br>595 sespective association studies identify susceptibility loci for epithelial ovarian cancer in east Asian 595 ssociation studies identify susceptibility loci for epithelial ovarian cancer in east Asian<br>596 women. Gynecol Oncol. 2019:153(2):343–55. women. Gynecol Oncol. 2019;153(2):343–55.
- 597 19. Manichaikul A, Peres LC, Wang X-Q, Barnard ME, Chyn D, Sheng X, et al.<br>598 Identification of novel epithelial ovarian cancer loci in women of African ancestry. Int J 598 Identification of novel epithelial ovarian cancer loci in women of African ancestry. Int J<br>599 Cancer. 2020 Jun 1;146(11):2987–98. Cancer. 2020 Jun 1;146(11):2987–98.
- <sup>600</sup>20. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric 601 Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis<br>602 (DIAGRAM) Consortium et al. Conditional and ioint multiple-SNP analysis of GWAS <sup>602</sup>(DIAGRAM) Consortium, et al. Conditional and joint multiple-SNP analysis of GWAS 603 summary statistics identifies additional variants influencing complex traits. Nat Genet.<br>604 2012 Mar 18:44(4):369–75, S1-3. <sup>604</sup>2012 Mar 18;44(4):369–75, S1-3.
- <sup>605</sup>21. Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, et al. 606 Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am J<br>607 Hum Genet. 2015 Oct 1;97(4):576–92. Hum Genet. 2015 Oct 1;97(4):576–92.
- 608 22. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019 16:10(1):1776. regression and continuous shrinkage priors. Nat Commun. 2019 16;10(1):1776.
- 610 23. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J,<br>611 et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 611 et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2<br>612 Mutation Carriers. JAMA. 2017 20:317(23):2402–16. Mutation Carriers. JAMA. 2017 20;317(23):2402-16.
- 613 24. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic Risk<br>614 Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 614 Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet.<br>615 2019 03:104(1):21–34. <sup>615</sup>2019 03;104(1):21–34.
- 616 25. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al.<br>617 63 Association analyses of more than 140,000 men identify 63 new prostate cancer 617 Association analyses of more than 140,000 men identify 63 new prostate cancer<br>618 susceptibility loci. Nat Genet. 2018:50(7):928–36. susceptibility loci. Nat Genet.  $2018;50(7):928-36$ .
- 619 26. Jia G, Lu Y, Wen W, Long J, Liu Y, Tao R, et al. Evaluating the Utility of Polygenic<br>620 Risk Scores in Identifying High-Risk Individuals for Eight Common Cancers. JNCI 620 Risk Scores in Identifying High-Risk Individuals for Eight Common Cancers. JNCI<br>621 Cancer Spectr. 2020 Jun:4(3):pkaa021. Cancer Spectr. 2020 Jun;4(3):pkaa021.
- 622 27. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, et al.<br>623 Population distribution of lifetime risk of ovarian cancer in the United States. Cancer <sup>623</sup>Population distribution of lifetime risk of ovarian cancer in the United States. Cancer

624 Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.<br>625 2015 Apr:24(4):671–6. <sup>625</sup>2015 Apr;24(4):671–6.

- 626 28. Yang X, Leslie G, Gentry-Maharaj A, Ryan A, Intermaggio M, Lee A, et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. 627 of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study.<br>628 J Med Genet. 2018;55(8):546–54. J Med Genet. 2018;55(8):546–54.
- 629 29. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer Risks<br>630 Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 630 Associated With Germline PALB2 Pathogenic Variants: An International Study of 524<br>631 Families. J Clin Oncol Off J Am Soc Clin Oncol. 2020 Mar 1:38(7):674–85. Families. J Clin Oncol Off J Am Soc Clin Oncol. 2020 Mar 1;38(7):674–85.
- 632 30. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al.<br>633 Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a 633 Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2020 Jun 16: susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2020 Jun 16;
- 635 31. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al.<br>636 BOADICEA: a comprehensive breast cancer risk prediction model incorporating 636 BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019 Aug:21(8):1708–18. genetic and nongenetic risk factors. Genet Med. 2019 Aug;21(8):1708–18.
- 638 32. Welcome to CanRisk [Internet]. [cited 2020 Aug 31]. Available from:<br>639 https://www.canrisk.org/ https://www.canrisk.org/
- 640 33. Chen K, Ma H, Li L, Zang R, Wang C, Song F, et al. Genome-wide association study<br>641 identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. 641 identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.<br>642 Nat Commun. 2014 Aug 19:5:4682. Nat Commun. 2014 Aug 19;5:4682.
- 643 34. Watkins WS, Rogers AR, Ostler CT, Wooding S, Bamshad MJ, Brassington A-ME, et al. Genetic variation among world populations: inferences from 100 Alu insertion 644 al. Genetic variation among world populations: inferences from 100 Alu insertion<br>645 bolymorphisms. Genome Res. 2003 Jul:13(7):1607–18. polymorphisms. Genome Res.  $2003$  Jul;13(7):1607–18.
- 646 35. Hu Y, Lu Q, Powles R, Yao X, Yang C, Fang F, et al. Leveraging functional annotations<br>647 in genetic risk prediction for human complex diseases. PLoS Comput Biol. 2017 647 in genetic risk prediction for human complex diseases. PLoS Comput Biol. 2017<br>648 Jun;13(6):e1005589. Jun;13(6):e1005589.

649

## **Figure captions**

#### **Figure 1: PRS model development using penalized regression and LDPred Bayesian approach**

**Figure 2: Cumulative risk of ovarian cancer between birth and age 80 by PRS percentiles and PRS models**. Shown are the cumulative risk of ovarian cancer risk in UK women by polygenic risk score percentiles. The lasso (A) and elastic net (B) penalized regression models were applied to individual level genotype data, while the stepwise (C) and S4 (D) models were applied to summary level statistics**.** 

**Figure 3: Association between the PLR PRS models and non-mucinous ovarian cancer by PRS percentiles.** Shown are estimated odds ratios (OR) and confidence intervals for women of European ancestry by percentiles of polygenic risk scores derived from lasso (A), elastic net (B), stepwise (C) and S4 (D) models relative to the middle quintile.

# **Figure 1: PRS model development using penalized regression and LDPred Bayesian approach.**



**Figure 2: Cumulative risk of ovarian cancer between birth and age 80 by PRS percentiles and PRS models** 





**Figure 3: Association between the PLR PRS models and non-mucinous ovarian cancer by PRS percentiles**